Bliss GVS Pharma: Anupam Rasayan takes control in 2026

What changed at Bliss GVS Pharma

Bliss GVS Pharma Limited, a listed pharmaceutical company, disclosed a completed change in control after Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited acquired a large equity stake. The company said its board took note of the reclassification of the erstwhile promoter and promoter group members to the “public” category following this control transfer. The update was tied to the completion of transactions under a share purchase agreement signed earlier in 2026 and an open offer process. The acquirer group was designated as the promoters with effect from September 28, 2026. Separately, related filings also referenced a SAST disclosure dated September 30 that corroborated the change in control and promoter reclassification.

Company profile and listing details

Bliss GVS Pharma has been listed on both the Bombay Stock Exchange and the National Stock Exchange since July 26, 2010. The BSE code is 506197 and the NSE ticker is BLISSGVS. The stock is in the BE series and carries ISIN INE416D01022. The company is classified under the Pharmaceuticals and Drugs sector. Bliss GVS Pharma was incorporated on December 11, 1984 as a public limited company and was promoted by Mr Gautam Ashra.

The acquirers and the control transfer

The company stated that Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited, acting as persons acting in concert (PAC), acquired control and became the new promoters. The change in control was stated to have occurred on September 28, 2026. The disclosure said the PAC acquired 5,09,84,595 equity shares representing 47.95% of the company’s equity share capital pursuant to the share purchase agreement. After subsequent steps, the combined holding of Anupam Rasayan (Acquirer) and the PAC rose to 5,32,36,264 equity shares, representing 50.07% of the equity share capital.

Share purchase agreement, deed of adherence, and open offer link

Bliss GVS Pharma linked the control transfer to the share purchase agreement dated May 23, 2026 and a deed of adherence dated July 17, 2026. The company said control changed after the transfer of promoter shares and the completion of the open offer. Separately, the “Change of Promoter” section noted that in May 2026 the company disclosed a proposed acquisition of approximately 43.28% of its paid-up equity share capital for Rs. 1,369 Cr, subject to regulatory approvals and other closing conditions. That disclosure also referenced a mandatory open offer for up to an additional 26% stake from public shareholders.

Promoter reclassification under SEBI Listing Regulations

The company said its board took note of the outgoing promoters’ intent to cease being promoter group members and to be reclassified as public shareholders. The disclosure referenced Regulation 31A(10) of the SEBI Listing Regulations in the context of this reclassification. The company also confirmed compliance with Regulation 31A(3)(b) and undertook to comply with Regulation 31A(4) regarding the reclassification process.

Outgoing promoter stake falls sharply

A key element of the disclosure was the steep reduction in the outgoing promoter and promoter group shareholding. The board update said the combined holding of the outgoing promoter group fell from 3,71,30,124 shares (34.82%) to 8,100 shares (0.01%) with effect from September 28, 2026. The table provided by the company showed that Narsimha Shibroor Kamath’s 30.51% holding moved to nil following completion.

Post-acquisition shareholding and promoter holding trend

Post-acquisition, the combined holding of the acquirer and PAC was disclosed at 5,32,36,264 shares or 50.07% of the equity share capital. Separately, the shareholding trend table included promoter holding data from September 2023 to June 2026, showing promoter holdings around the mid-35% level prior to the control transfer. The latest quarter promoter holding mentioned was 35.01%, while the immediately preceding quarter promoter holding was stated as 35.36%. The data table listed promoter holding values such as 35.36% in March 2026 and 35.01% in June 2026.

Board changes and disclosures around the deal

The narrative included that the acquirer group reconstituted the board with three additional directors after consummating the acquisition of control on September 28. The company’s September 28 board update and the September 30 SAST disclosure were described as together confirming the completed change in control and promoter reclassification. In a separate disclosure, Catalyst Trusteeship Limited reported creation of a pledge over 5,09,84,595 equity shares, representing a 47.95% stake, created on September 30, 2026 while acting as a debenture trustee.

Why this matters for investors tracking control and governance

For shareholders, the disclosure is significant because it formalises a change in who controls the company and who is treated as promoter under market regulations. The shift from the earlier promoter group to a new promoter set can affect governance, board composition, and future strategic priorities, although the company’s announcement focused on regulatory classification and completion mechanics. The reduction of outgoing promoters’ holding from 34.82% to 0.01% also changes the ownership map materially. Investors typically monitor such events through board notes, SAST disclosures, and shareholding pattern updates, which in this case were referenced with specific dates and share counts.

Conclusion

Bliss GVS Pharma’s filings around September 28-30, 2026 show a completed change in control, with Anupam Rasayan India and Mates Visa Consultancy becoming promoters after taking the combined holding to 50.07%. The board’s note on promoter reclassification and the detailed pre and post shareholding table document the outgoing promoter group’s exit to the public category. The next procedural steps, as stated, are tied to continued compliance with Regulation 31A requirements referenced by the company.